Non-Stimulant Treatment for ADHD in Adults: A Complete Guide to Your Options

If you've been told ADHD medication isn't an option for you, or you've tried stimulants and they didn't work, you're not out of luck in terms of ADHD treatment options. Non stimulant treatment for ADHD in adults is a real, evidence-supported category of care, and for many people it works as well as stimulants. For others, it's the only safe option clinically. And for a growing number of adults caught in the ongoing stimulant shortage, non-stimulants have become a practical lifeline.

This guide covers the four main non-stimulant medications used as an alternative to stimulants for ADHD in adults, including atomoxetine (Strattera), viloxazine ER (Qelbree), guanfacine, and bupropion.

We'll explain how each one works, what to expect when starting one, and how to decide whether a non-stimulant approach is right for you.

When Non-Stimulant Treatment for ADHD in Adults Makes Sense

Stimulants are typically the first medications considered for ADHD because they have the strongest evidence base. They aren't right for everyone, though. Non stimulant treatment for ADHD in adults becomes the preferred or required path in several common scenarios:

• Cardiovascular concerns: Stimulants modestly increase heart rate and blood pressure. For adults with arrhythmias, uncontrolled hypertension, structural heart disease, or other significant cardiac conditions, research on adult ADHD medications and cardiovascular risk supports shifting toward non-stimulants.
• Substance use history: Stimulants are Schedule II controlled substances with abuse potential. For adults with a current or past substance use disorder, or strong family history of one, clinical research on ADHD and substance use supports prioritizing non-stimulants, which have no abuse potential.
• Co-occurring anxiety: Stimulants can worsen anxiety symptoms in some people. For adults whose anxiety treatment and ADHD care need to coexist, non-stimulants like atomoxetine often handle both more gracefully.
• Bipolar disorder: Stimulants carry a risk of triggering mania or mood instability in adults with bipolar disorder. Non-stimulants are typically safer in this population.
• Stimulant non-response or intolerance: Roughly 30 percent of adults with ADHD don't achieve adequate symptom control on stimulants, or experience side effects that make continuing impractical. For these patients, non-stimulants are the natural next step.

There's also a practical layer worth naming. The ongoing stimulant shortage has made consistent access to medications like Adderall and Vyvanse unreliable for many adults. Non-stimulants, which aren't controlled substances and aren't subject to DEA production quotas, have largely sidestepped this issue.

How Non-Stimulant Treatment for ADHD in Adults Works Differently Than Stimulants

The two categories of ADHD medication target similar brain systems through different mechanisms, and that difference shapes everything about how they feel to take.

1. Stimulants for ADHD

Stimulants like methylphenidate and amphetamine work by quickly increasing dopamine and norepinephrine availability in the prefrontal cortex. The effect is rapid, often within an hour, and wears off as the medication clears the body. That's why stimulant dosing typically maps to a workday and why some people feel a noticeable shift on and off the medication.

2. Non stimulants for ADHD

Non-stimulant treatment for ADHD in adults works differently. Atomoxetine and viloxazine selectively inhibit norepinephrine reuptake, gradually building steady-state levels over weeks. Guanfacine and clonidine act on alpha-2 adrenergic receptors, supporting prefrontal regulation through a separate pathway. Bupropion blocks both norepinephrine and dopamine reuptake. None of these create the rapid spike-and-clear pattern stimulants do.

The practical implications:

• Onset takes longer: Most non-stimulants take four to eight weeks to reach full effect, compared to hours for stimulants.
• Coverage is steady: Once a non-stimulant reaches therapeutic levels, it provides consistent, all-day coverage without the on-off pattern stimulants can produce.
• No rebound or crash: Because there's no rapid clearance, non-stimulants don't produce the late-afternoon dip many adults experience with shorter-acting stimulants.
• Not controlled substances: Non-stimulants aren't scheduled by the DEA, which means no special prescribing rules, no concerns about misuse, and far fewer barriers in telehealth contexts.

For a side-by-side comparison of stimulants and non-stimulants, our broader treatment for ADHD in adults guide goes into more depth on stimulants specifically.

The Main Non-Stimulant Treatment Options for ADHD in Adults

There are four medications most commonly used in non stimulant treatment for ADHD in adults, plus a couple of less common options. Two of them, atomoxetine and viloxazine, are FDA-approved specifically for adult ADHD. Three others, guanfacine, clonidine and bupropion, are FDA-approved for related uses and prescribed off-label for adult ADHD with strong clinical evidence.

The comparison table below lays out how they differ on mechanism, evidence base, timeline, and what each tends to do well.

1. Atomoxetine (Strattera)

Atomoxetine, sold under the brand name Strattera and now widely available as a generic, has the deepest evidence base among non-stimulant ADHD medications and is the most commonly prescribed non-stimulant for adult ADHD. It works as a selective norepinephrine reuptake inhibitor, increasing norepinephrine availability in the prefrontal cortex. A recent systematic review and meta-analysis of 15 randomized controlled trials in adults found atomoxetine significantly more effective than placebo at reducing core ADHD symptoms, with a moderate effect size.

Atomoxetine takes four to eight weeks to reach full effect. Side effects can include nausea, decreased appetite, dry mouth, fatigue, and modest increases in blood pressure or heart rate. Liver function is typically monitored. For adults who can tolerate the early adjustment period, atomoxetine often provides reliable, steady symptom control without the volatility stimulants can carry.

2. Viloxazine ER (Qelbree)

Viloxazine extended-release, marketed as Qelbree, received FDA approval for adult ADHD in 2022, making it the newest non-stimulant option. Like atomoxetine, viloxazine inhibits norepinephrine reuptake, but it also has additional serotonergic activity that may contribute to its effects. A head-to-head retrospective study comparing viloxazine ER to atomoxetine found that 87 percent of adults on viloxazine reported a positive response at two weeks, compared to 13 percent on atomoxetine, suggesting faster onset.

Side effects of Qelbree can include somnolence, decreased appetite, nausea, and headache. Viloxazine tends to be better tolerated than atomoxetine for many patients. For adults newly considering non-stimulant treatment, it's increasingly chosen as a first-line option.

3. Guanfacine ER (Intuniv)/Clonidine

Guanfacine extended-release and clonidine are an alpha-2 adrenergic agonist that supports prefrontal cortex regulation through a different pathway than the reuptake inhibitors. It's FDA-approved for ADHD in children and adolescents 6 to 17 and prescribed off-label for adults, where clinical use is well-established.

Guanfacine and clonidine tend to work better for hyperactivity, impulsivity, and emotional reactivity than for pure inattention. It can be sedating, especially when starting, and lowers blood pressure modestly. For adults whose ADHD presentation skews toward impulsivity or emotional dysregulation, or who have co-occurring anxiety where mild sedation is acceptable, it can be a strong fit. It's also commonly combined with stimulants when behavioral and attentional symptoms both need addressing.

4. Bupropion (Wellbutrin)

Bupropion is FDA-approved as an antidepressant and prescribed off-label for ADHD with reasonable clinical evidence. It blocks both norepinephrine and dopamine reuptake, which gives it a mechanism more similar to stimulants than other non-stimulants have. For adults with co-occurring depression, bupropion can address both conditions with a single medication.

It typically takes two to six weeks to show ADHD benefit. Side effects can include insomnia, dry mouth, and a small increased risk of seizures at higher doses. For adults whose depression psychiatry and ADHD care should sit together in one plan, bupropion is often the answer.

Clonidine extended-release (Kapvay) is also sometimes used. Like guanfacine, it's an alpha-2 agonist, but it tends to be more sedating and is less commonly chosen first.

What to Expect From Non-Stimulant Treatment for ADHD in Adults

Starting non stimulant treatment for ADHD in adults looks different from starting a stimulant, and knowing what to expect helps a lot.

The first two weeks usually feel like not much is happening. That's normal. Non-stimulants don't produce the rapid effect stimulants do, and the temptation to give up early is real but usually misplaced.

By week four, most people on viloxazine ER notice meaningful symptom changes. Atomoxetine typically takes longer, with most patients reaching full effect between weeks six and eight. Guanfacine and bupropion fall somewhere in between, often showing benefit by week three or four. Dose adjustments along the way are normal and expected.

Side effects, when they appear, usually show up in the first two to three weeks and often improve with time. The most common ones by medication:

• Atomoxetine and viloxazine: Nausea, decreased appetite, fatigue, and sometimes initial mood or sleep changes.
• Guanfacine/clonidine: Sedation, lowered blood pressure, and dry mouth.
• Bupropion: Insomnia, dry mouth, and occasional jitteriness.

Combining non-stimulants with stimulants is common when one alone isn't enough. The most frequent pairing is guanfacine plus a stimulant, which can address both attentional and behavioral symptoms with a lower overall stimulant dose. This is a clinical decision worth discussing openly with your provider.

How to Decide Between Stimulant and Non-Stimulant Treatment for ADHD in Adults

The choice between stimulant and non-stimulant medication isn't always either-or, and it's rarely permanent. It depends on a handful of factors a psychiatric provider can help weigh:

1. Health history: Cardiovascular conditions, history of mania, seizure disorders, and substance use history all influence which medications are safe to try.
2. Co-occurring conditions: Anxiety, depression, sleep disorders, and bipolar disorder can each shift the balance. For some combinations, non-stimulants are simply the better integrated option.
3. Prior treatment response: Adults who've tried stimulants and didn't tolerate them, didn't respond, or experienced unmanageable side effects often do well on non-stimulants.
4. Practical considerations: Comfort with taking a controlled substance, access through telehealth (which has fewer restrictions for non-stimulants), and the ongoing stimulant shortage all factor in.
5. Symptom presentation: Predominantly hyperactive-impulsive symptoms often respond well to guanfacine. Predominantly inattentive symptoms often do better with atomoxetine or viloxazine.

For some adults, stimulants are the obvious first choice and non-stimulants come later if needed. For others, non stimulant treatment for ADHD in adults is the clear starting point. For a meaningful share of patients, a combination works better than either alone. The right approach is the one matched to your specific situation, refined over time as you and your provider learn what works.

What a Telehealth Evaluation for Non-Stimulant ADHD Treatment Looks Like

When non stimulant treatment for ADHD in adults is on the table, the evaluation focuses on a few specific areas alongside the standard ADHD workup:

1. Detailed clinical history: Including any cardiac, psychiatric, or substance use history that influences medication selection.
2. Symptom presentation: Whether attention, hyperactivity, impulsivity, or emotional reactivity is dominant, since different non-stimulants target these differently.
3. Co-occurring condition screening: Particularly for anxiety, depression, and bipolar disorder, all of which shape the choice of medication.
4. Prior treatment review: What you've tried, how it went, and what you'd want to do differently this time.
5. Goal setting and preference discussion: What you're hoping a medication will help with, and what trade-offs you're willing to make.

Because non-stimulants aren't controlled substances, they're particularly well-suited for telehealth prescribing. There are no in-person requirements, no special DEA scheduling rules, and far fewer barriers than stimulants face in the current regulatory landscape. For Virginia residents, our psychiatric providers can complete the full evaluation and follow-up through telehealth visits, and the patient resources page outlines what to expect before your first appointment.

Conclusion: Finding Non-Stimulant ADHD Treatment Support in Virginia

Non stimulant treatment for ADHD in adults isn't a backup plan or a lesser option. For many people, it's the right first choice. For others, it's the right second choice after a stimulant trial didn't go well. Either way, the medications available today, especially atomoxetine and viloxazine ER, have meaningful evidence supporting their use and offer real symptom relief without the trade-offs stimulants can carry.

Compass Behavioral Health provides ADHD treatment to Virginia residents through telehealth, statewide. Our providers can evaluate you, build a personalized plan, and prescribe non-stimulant medications without the access friction stimulants can involve. If you've been wondering whether non stimulant treatment for ADHD in adults might be a fit, or you've tried stimulants and want to consider another path, we can help. For the broader picture of all your options, including stimulants, therapy, and lifestyle support, see our complete guide to treatment for ADHD in adults. Schedule an appointment today.